Background: Hyperglycemia is commonly seen in critically ill patients. This disorder was also seen in coronavirus disease 2019 (COVID-19) patients and was associated with a worse prognosis. The current study determined the prevalence, risk factors, and prognostic implications of hyperglycemia in COVID-19 patients.
Method: This was a retrospective observational study performed in an intensive care unit for COVID-19 patients. Electronic data of COVID-19 patients admitted to the intensive care unit from August 2nd to October 15th, 2021, were collected. Patients were divided into non-hyperglycemia, hyperglycemia in diabetic patients, and hyperglycemia in non-diabetic patients. Primary outcomes were 28-day and in-hospital mortalities. Multinomial logistic regression and multivariable Cox regression models were used to determine the risk factors for hyperglycemia and mortality, respectively.
Results: Hyperglycemia was documented in 65.6% of patients: diabetic patients (44.8%) and new-onset hyperglycemia (20.8%). In-hospital and 28-day mortality rates were 30.2% and 26.1%, respectively. Respiratory failure, corticosteroid therapy, and a higher level of procalcitonin were risk factors for hyperglycemia in diabetic patients, whereas cardiovascular diseases, respiratory failure, and higher aspartate aminotransferase/glutamate aminotransferase ratio were risk factors for hyperglycemia in non-diabetic patients. The risk of the 28-day mortality rate was highest in the new-onset hyperglycemia (hazard ratio [HR] 3.535, 95% confidence interval [CI] 1.338-9.338, p=0.011), which was higher than hyperglycemia in type 2 diabetes mellitus patients (HR 1.408, 95% CI 0.513-3.862, p=0.506).
Conclusion: Hyperglycemia was common in COVID-19 patients in the intensive care unit. Hyperglycemia reflected the disease severity but was also secondary to therapeutic intervention. New-onset hyperglycemia was associated with poorer outcomes than that in diabetic patients.
Since December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) has spread rapidly across the globe and claimed more than 511 million infected cases and 6.22 million deaths, making it one of the deadliest plagues in the human history [1].
Chronic comorbidities are common in severe and critical COVID-19 patients [2]. Type 2 diabetes mellitus (T2DM) was the second most frequent chronic disease in COVID-19 patients and was a risk factor for severity and mortality in this group of patients [3-5]. Compared to baseline hemoglobin A1C (HbA1C), acute hyperglycemia in diabetes is a stronger predictor of death in critically ill diabetic patients admitted to intensive care units (ICU) [6,7]. Hyperglycemiais also common among non-diabetic patients in ICU, and the more severe hyperglycemia is, the higher the risk of respiratory failure, infection, and mortality [8,9]. Interestingly, acute hyperglycemia is more harmful to non-diabetic patients than to diabetic patients in the ICU [10]. It was demonstrated that diabetes and hyperglycemia were the risk factors for a poorer prognosis of the previous severe acute respiratory syndrome (SARS) disease [11]. Early in the COVID-19 pandemic, it was recognized that pre-existing T2DM, newly diagnosed T2DM, and new-onset hyperglycemia were associated with a worse prognosis in COVID-19 patients [12,13].
Hyperglycemia in critically ill patients is caused by multiple pathological conditions, including inflammatory reactions. Cytokine storm plays a central role in the pathology of COVID-19 [14]. It is not surprising that hyperglycemia occurs in COVID-19 patients [5]. However, different from other critical diseases and also different from those in the early phase of the COVID-pandemic, the wide adoption of corticosteroid therapy (CST), especially mini pulse CST in the second half of the year 2021, might affect the epidemiology and the outcome of acute hyperglycemia in COVID-19 patients. This study was performed in this clinical context to investigate the incidence, the possible risk factors of hyperglycemia, and the effect of hyperglycemia in 28-day in-hospital mortality in COVID-19 patients.
This retrospective observational study recruited all COVID-19 patients, confirmed with positive reverse transcription polymerase chain reaction (RT-PCR) for SARS-CoV-2, admitted to our COVID-19 intensive care center from August 2nd to October 15th, 2021. The diagnosis of COVID-19 was based on a positive RT-PCR for SARS-CoV-2 following the World Health Organization (WHO) interim guidance [15]. We excluded patients with type 1 diabetes mellitus, pregnancy, patients under 18 years of age, patients in whom a presence of a T2DM was not confirmed or excluded with certainty, and patients whose electronic medical record was not well documented. This center, a part of a field hospital, was a tertiary referral center established during the peak of the COVID-19 pandemic that ravaged the city of 10 million inhabitants.
The relevant data were extracted from the electronic medical records. Data of each patient were collected by two investigators. Any collected information that required further clarification was reviewed by the most senior investigatorsor by the whole team.
We mostly used capillary blood glucose (BG) values in clinical practice. The venous BG from the central laboratory was issued on a daily checkup or on demand, usually in combination with other hematological, biochemical, and immunological tests. Should the venous BG report an abnormal result, we used the capillary BG for closer monitoring. This study used the capillary BG values for analysis. All patients had their capillary BG values measured on admission to the ICU.
Hyperglycemia was defined when a patient had at least two random BG values >180 mg/dL in 24 hours. Based on the BG level during the hospital stay and history of T2DM, we divided the patients into three groups as follows:
Non-hyperglycemia: non-diabetic or T2DM patients who did not meet the criteria of hyperglycemia during their hospital stay;
Hyperglycemia with T2DM: at least two random BG values >180 mg/dL in 24 hours and the patient had been previously diagnosed with T2DM; and
New-onset hyperglycemia: at least two random BG values >180 mg/dL in 24 hours and the T2DM was excluded.
The primary outcome was 28-day and in-hospital mortality in the three groups mentioned above.
The statistical analysis was performed using the SPSS Statistics, version 28.0.1.0 (IBM, Armonk, NY, USA). Data are expressed as frequency (percentage) for categorical variables; mean standard deviation, and median (interquartile range) for continuous parameters. The one-way analysis of variance (ANOVA) was used to compare three groups. In univariate analysis, the chi-square test was used for categorical parameters and the Wilcoxon rank-sum test for continuous parameters to compare the survival and death groups. The variables that had significance in the univariate analysis were included in multivariate Cox (proportional-hazards) regression to identify the independent risk factors of in-hospital mortality. All statistical tests were two-tailed, and a p-value of less than 0.05 was considered statistically significant.
The present study was approved by the Institutional Review Board of University Medical Center, Ho Chi Minh City, Vietnam (approval number: 08022022/HDDD-BVDHYD). The informed consent for participation was obtained from the patients or their family members. All methods were performed in accordance with the Declaration of Helsinki.
After screening, 517 patients who met the inclusion criteria were recruited for the study. The demographic and clinical characteristics of the three groups on admission are presented in Table 1. The incidence of hyperglycemia was 65.6%. The non-hyperglycemia group was younger than the two groups with hyperglycemia. The two groups with hyperglycemia were comparable in age and body mass index (BMI), but the T2DM hyperglycemia group had a significantly higher percentage of female patients (62.9% vs. 52.3%). Comorbidities were common in three groups, with arterial hypertension more dominant in the T2DM hyperglycemia group. On admission, clinical parameters were not significantly different between the two groups with hyperglycemia. The respiratory failure in the non-hyperglycemia was less severe than in the rest. In the non-hyperglycemia group, there were 24 diabetic patients (13.5%). The new-onset hyperglycemia incidence in non-diabetic patients was 41.0% (107/261 patients).
As well recognized as a factor inducing hyperglycemia, CST was also investigated in the current study. Briefly, the new-onset hyperglycemia group seemed to receive slightly higher doses of corticosteroids than the two other groups.
The laboratory results on the admission of the three groups of patients are presented in Table 2. Both T2DM and new-onset hyperglycemia groups demonstrated higher levels of inflammatory markers, namely white blood cell counts (WBC), C-reactive protein (CRP), D-dimer, and interleukin-6, except for the plasma fibrinogen concentration. The procalcitonin concentrations of the three groups were statistically different in absolute values as well as in terms of the proportions of patients with procalcitonin levels equal to or above 0.5 ng/mL. The renal function of T2DM hyperglycemia and new-onset hyperglycemia groups was more depressed than the non-hyperglycemia group. Liver function tests in three groups showed a mild degree of hepatic damage with a higher aspartate aminotransferase/glutamate aminotransferase (AST/ALT) ratio in the new-onset hyperglycemia group.
We further investigated the independent risk factors of T2DM hyperglycemia and new-onset hyperglycemia. The analysis results are presented in Table 3. The invasive mechanical ventilation on admission, procalcitonin level of more than 0.5 ng/mL, and CST were the risk factors for hyperglycemia in T2DM patients. In non-diabetic patients, invasive mechanical ventilation on admission was still an important independent risk factor for hyperglycemia. In addition, the presence of cardiovascular diseases and the high AST/ALT ratio were also the risk factors for hyperglycemia in non-diabetic COVID-19 patients.
Out of 517 patients enrolled in the study, 156 (30.2%) patients died in the hospital. The 28-day mortality was 3.9% (7/178), 34.5% (80/232), and 44.9% (48/107) in the non-hyperglycemia, T2DM hyperglycemia, and new-onset hyperglycemia group, respectively.
The hazard ratio (HR) for death with adjustment for other risk factors was significantly increased among patients with hyperglycemia with or without T2DM compared to those of the non-hyperglycemia group (Figure 1).
We also noticed that the percentage of patients requiring invasive mechanical ventilation was significantly higher (70%) in the new-onset hyperglycemia groupthan in the T2DM hyperglycemia group (51%) and in patients without hyperglycemia (9%).
We also performed a multivariable Cox regression model to identify the risk factors of 28-day in-hospital mortality. The results are presented in Table 4.Out of 13 parameters investigated, higher age, increased mean glucose level, D-dimer, new-onset hyperglycemia, PaO2/FiO2 ratio on admission, PCT 0.5 ng/mL, and average daily corticosteroid dose were independently associated with increased risk of mortality. Interestingly, the new-onset hyperglycemia was associated with an important increase in in-hospital mortality (HR 3.535, 95% confidence interval [CI] 1.338-9.338, p = 0.011).
It is well established that diabetes significantly increases the risk of developing and dying from infectious diseases [16,17]. Hyperglycemia is a common manifestation directly correlated with increased mortality or morbidity in critically ill patients [18-20]. Early in the COVID-19 pandemic, the first studies found that diabetes was one of the most common comorbidities in COVID-19 patients [4,21]. In COVID-19 patients, hyperglycemia may be further accentuated due to the intense cytokine storm [22]. Little evidence existed on whether hyperglycemia in COVID-19 patients bears any significant prognostic implication. The current study investigated the incidence of hyperglycemia, the risk factors of hyperglycemia in diabetic and non-diabetic COVID-19 patients, and the impact of hyperglycemia on mortality and morbidity.
The incidence of hyperglycemia was noticeably high (65.6%) in the studied population. Hyperglycemia-associated mortality in critically ill patients and the beneficial effects of glycemic control have been intensively studied since the breakthrough work by Van den Berghe et al. [8]. These studies have shed light on the mechanism of hyperglycemia and its harmful consequence in this group of patients. The mechanisms of hyperglycemia in COVID-19 patients are likely multifactorial and were discussed in depth elsewhere [22]. The incidence of hyperglycemia in our study was higher than that in a study by Bode et al., including COVID-19 patients from 88 hospitals in the United States, where hyperglycemia was documented in 40% of patients [23]. Several possible reasons for the higher incidence of hyperglycemia in the current study should be mentioned. Our study was conducted in a field hospital built when the COVID-19 pandemic reached its peak, causing overwhelming in the healthcare facility and human resources. These factors might reduce the required adhesion to protocolized management, including glycemic control in critically ill patients. Furthermore, the current study was performed after nearly two months of strict travel restrictions and city lockdown. The consequent lifestyle change, reduced physical activity, poorly controlled diets, and difficulty in medical access, especially the diabetic medications, might partially explain the high incidence of hyperglycemia [22].
The new-onset hyperglycemia was documented in 20.8% of all patients and 41.0% of non-diabetic COVID-19 patients. This incidence was lower than that (28.4%) in the retrospective study by Li et al. [13]. More importantly, the widespread CST therapy, especially the mini-pulse dose, was obviously responsible for hyperglycemia, as shown in Table 3. Previous studies showed that 53-70% of non-diabetic individuals developed steroid-induced hyperglycemia after being treated with high-dose corticosteroids [24,25].
The 28-day and the in-hospital mortality rates were 26.1% and 30.2%, respectively. Our center was the tertiary referral hospital receiving the most severe COVID-19 patients during the zenith of the pandemic. This might explain the higher mortality rate compared to previous studies from China and United States. Besides a higher 28-day mortality, the new-onset hyperglycemia was also related to an increased need for mechanical ventilation during the hospitalization (70%) compared to the T2DM hyperglycemia group (51%). The current study confirmed once again the findings in previous works [3,26]: the new-onset hyperglycemia was associated with poorer outcomes in COVID-19 patients. Compared to the non-hyperglycemia group, the risk of the 28-day mortality rate was highest in the new-onset hyperglycemia (HR 3.535, 95% CI 1.338-9.338, p = 0.011), which was higher than T2DM hyperglycemia (HR 1.408, 95% CI 0.513-3.862, p = 0.506). The clinical and laboratory findings in T2DM hyperglycemia and new-onset hyperglycemia in the current study indicated the more severe manifestations in these two groups compared to the rest. At the first glance, the severity in the two hyperglycemia groups was not significant. However, the levels of CRP (72.7 mg/L vs. 57.9 mg/L), D-dimer (1540 ng/mL vs. 1139 ng/mL), AST/ALT ratio (1.5 vs. 1.2), and the proportion of patients requiring invasive mechanical ventilation (30.8% vs. 23.3%) on admission were higher in the new-onset than in the T2DM hyperglycemia group. This difference in severity may explain why the new-onset hyperglycemia group had poorer outcomes than the T2DM hyperglycemia group. It has been demonstrated that the relationship between hyperglycemia and COVID-19 is a complex and bidirectional interaction: hormone dysregulations with insulin resistance and the intense cytokine storm in COVID-19 induce hyperglycemia. Hyperglycemia, in turn, adversely affects the host immune response [27], increases inflammatory cytokines [28], and facilitates SARS-CoV-2 replication [29]. More importantly, hyperglycemia worsened the progression of respiratory failure [26]. T2DM has been well proven as one of the most common chronic comorbidities and an important risk factor for poorer outcomes and higher mortality in COVID-19 patients. Our study reinforced the evidence in a new demographic, therapeutic, and socio-economic population. The important finding was that the new-onset hyperglycemia patients were associated with higher mortality and other secondary outcomes compared to T2DM patients who developed hyperglycemia during their hospitalization due to COVID-19. The new-onset hyperglycemia mirrored the severity of COVD-19 disease and adversely affected the clinical course of these patients. Therefore, new-onset hyperglycemia is a strong predictor of severity in COVID-19 patients.
Hyperglycemia was documented in approximately two-thirds of severe and critical COVID-19 patients admitted to ICU. Hyperglycemia in patients with T2DM was more frequently seen and two-foldhigher than the new-onset hyperglycemia. The new-onset hyperglycemia group had the highest 28-day and in-hospital mortality rates, followed by the T2DM hyperglycemia group. The lowest mortality rates were documented in the non-hyperglycemia group. Similarly, the percentage of patients requiring invasive mechanical ventilation was significantly higher in the new-onset hyperglycemia group than in the T2DM hyperglycemia group and in patients without hyperglycemia. CST was the strongest independent risk factor for hyperglycemia in T2DM patients, whereas respiratory failure, reflected by the proportion of patients requiring invasive mechanical ventilation upon admission, was the strongest independent risk factor of hyperglycemia in non-diabetic patients. New-onset hyperglycemia was the most important risk factor for death in COVID-19 patients. The present study suggests that BG levels should be actively monitored in severe and critical COVID-19 patients. The occurrence of hyperglycemia in these patients, especially those without a previous diagnosis of T2DM, should be considered a marker of severity and worse outcomes. More studies are required to elucidate the likely multifactorial mechanisms of new-onset hyperglycemia in COVID-19 and the bidirectional interaction between new-onset hyperglycemia and severity in COVID-19 disease. We also need a prospective study investigating the impact of glycemic control in this group of patients and other similar diseases.
Continued here:
Hyperglycemia in Severe and Critical COVID-19 Patients: Risk Factors and Outcomes - Cureus
- As 2024 Travel Hits Pre-Covid Levels, Here's When To Go To Europe - Forbes - March 10th, 2024 [March 10th, 2024]
- Comparison of Impressions of COVID-19 Vaccinations Stratified by the Number of Vaccinations Among Japanese ... - Cureus - March 10th, 2024 [March 10th, 2024]
- Effect of the COVID-19 pandemic on mental health visits in primary care: an interrupted time series analysis from nine ... - The Lancet - March 10th, 2024 [March 10th, 2024]
- Faith and rehab keep Southwick woman on path to recovery from COVID - MassLive.com - March 10th, 2024 [March 10th, 2024]
- China to draw on Covid-19 experience to tackle future pandemics - theSun - March 10th, 2024 [March 10th, 2024]
- Free COVID tests through USPS are ending todayhere's where to get tests online - Reviewed - March 10th, 2024 [March 10th, 2024]
- Concern about COVID reaches record low across political spectrum: Survey - The Hill - March 10th, 2024 [March 10th, 2024]
- He Had 217 Covid Shots Without Side Effects, Study Finds - The New York Times - March 10th, 2024 [March 10th, 2024]
- A Man Got 217 COVID-19 Vaccines. Here's What Happened - TIME - March 10th, 2024 [March 10th, 2024]
- German man vaccinated 217 times against covid with no ill effects - The Washington Post - March 10th, 2024 [March 10th, 2024]
- Andrew Cuomo Faces House Subpoena Over Covid Deaths in Nursing Homes - The New York Times - March 10th, 2024 [March 10th, 2024]
- It's been 4 years since COVID hit Michigan. For Long COVID patients, the pandemic isn't over. Michigan Advance - Michigan Advance - March 10th, 2024 [March 10th, 2024]
- 4th Anniversary of the Covid-19 Pandemic - erienewsnow.com - March 10th, 2024 [March 10th, 2024]
- Reflecting on 4 years of the COVID-19 pandemic and discussing what's to come - WBUR News - March 10th, 2024 [March 10th, 2024]
- CDC shortens 5-day COVID isolation, updates guidance on masks and testing in new 2024 recommendations - CBS News - March 10th, 2024 [March 10th, 2024]
- Father, daughter convicted in fraud related to COVID-19 relief - The Cincinnati Enquirer - February 7th, 2024 [February 7th, 2024]
- Supreme Court to weigh whether Covid misinformation is protected speech - STAT - February 7th, 2024 [February 7th, 2024]
- Oklahoma leads country in long Covid - 2 News Oklahoma KJRH Tulsa - February 7th, 2024 [February 7th, 2024]
- MCFR firefighter dies after battle with COVID-19 - WCJB - February 7th, 2024 [February 7th, 2024]
- Audio-based AI classifiers show no evidence of improved COVID-19 screening over simple symptoms checkers - Nature.com - February 7th, 2024 [February 7th, 2024]
- Hidden death toll of COVID-19 pandemic revealed - Earth.com - February 7th, 2024 [February 7th, 2024]
- Switching arms improves effectiveness of two-dose vaccinations, OHSU study suggests - OHSU News - February 7th, 2024 [February 7th, 2024]
- Tributes paid to Irish health official 'central' to EU Covid-19 response - The Irish Times - February 7th, 2024 [February 7th, 2024]
- Court: Not wearing mask during COVID-19 health emergency isn't protected speech - Honolulu Star-Advertiser - February 7th, 2024 [February 7th, 2024]
- One arm or two? How you get vaccinated may make a difference - The Seattle Times - February 7th, 2024 [February 7th, 2024]
- 70% of kindergarteners didn't pass readiness test in pandemic, study estimates - University of Minnesota Twin Cities - February 7th, 2024 [February 7th, 2024]
- USS Theodore Roosevelt sailors roam free on Guam for first time since COVID-19 outbreak - Stars and Stripes - February 7th, 2024 [February 7th, 2024]
- Pandemic linked to 14% increase in underweight children in India - Medical Xpress - February 7th, 2024 [February 7th, 2024]
- COVID and travel: Should I still wear a mask on the plane? - USA TODAY - February 7th, 2024 [February 7th, 2024]
- Vaccine hesitancy and equity: lessons learned from the past and how they affect the COVID-19 countermeasure in ... - Globalization and Health - February 7th, 2024 [February 7th, 2024]
- Increase in STIs Among Adolescents Witnessed During COVID-19 Pandemic - Drug Topics - February 7th, 2024 [February 7th, 2024]
- VDH: COVID deaths not seeing decline - Vermont Biz - February 7th, 2024 [February 7th, 2024]
- US outpatient care for serious mental health issues declined during COVID-19 - University of Minnesota Twin Cities - February 7th, 2024 [February 7th, 2024]
- COVID-19 Vaccination in a Patient With Gluten Enteropathy: A Case Report - Cureus - February 7th, 2024 [February 7th, 2024]
- COVID-19 cases drop, but still lots of flu, RSV cases in Erie County - GoErie.com - February 7th, 2024 [February 7th, 2024]
- Lives versus livelihoods: The COVID-19 trade-off from an epidemiological-economic perspective - CEPR - February 7th, 2024 [February 7th, 2024]
- Weatherhead's Jonathan Ernest notes economic changes of childcare facilities following COVID-19 pandemic - The Daily | Case Western Reserve University - February 7th, 2024 [February 7th, 2024]
- U.S. adults face distress, unequal mental health care access during the COVID-19 era - News-Medical.Net - February 7th, 2024 [February 7th, 2024]
- Simnotrelvir to reduces the symptoms of mild to moderate COVID-19 - 2 Minute Medicine - February 7th, 2024 [February 7th, 2024]
- Vaccine Effectiveness: Which COVID-19 Shots Offer the Most Protection? - SciTechDaily - February 7th, 2024 [February 7th, 2024]
- New evidence confirms COVID-19 vaccination in pregnancy is safe for babies - Gavi, the Vaccine Alliance - February 7th, 2024 [February 7th, 2024]
- Audit Committee co-chairs, Evers at odds over interest from COVID-19 funds - WisPolitics.com - February 7th, 2024 [February 7th, 2024]
- Evaluation of Olfactory Dysfunction Among COVID-19 Patients in Baghdad, Iraq - Cureus - February 7th, 2024 [February 7th, 2024]
- COVID-19's impact on early education: Retrospective study shows decrease in kindergarten readiness - News-Medical.Net - February 7th, 2024 [February 7th, 2024]
- Rutgers researchers work on breakthrough COVID-19 treatment | Video - NJ Spotlight News - February 7th, 2024 [February 7th, 2024]
- Curious Iowa: Has the state spent all of its COVID-19 relief funding? - The Gazette - October 16th, 2023 [October 16th, 2023]
- Accelerating into Immunization Agenda 2030 with momentum from ... - Infectious Diseases of Poverty - BioMed Central - October 16th, 2023 [October 16th, 2023]
- Study Uncovers Why Young Children Suffer Less Severe COVID-19 - Technology Networks - October 16th, 2023 [October 16th, 2023]
- Wenstrup, Select Subcommittee Majority Members Investigate ... - House Committee on Oversight and Reform | - October 16th, 2023 [October 16th, 2023]
- With COVID-19 emergency orders lifted, employers seek guidance ... - Hartford Business Journal - October 16th, 2023 [October 16th, 2023]
- Computer-aided diagnosis of chest X-ray for COVID-19 diagnosis in ... - Nature.com - October 16th, 2023 [October 16th, 2023]
- Maternal COVID-19 Vaccination, Infection Boosts Infant Antibody ... - Contagionlive.com - October 16th, 2023 [October 16th, 2023]
- Three Middlesex County Individuals Admit COVID-19 Fraud ... - Department of Justice - October 16th, 2023 [October 16th, 2023]
- Seventeen Broward Sheriff's Office Employees Charged with COVID ... - Department of Justice - October 16th, 2023 [October 16th, 2023]
- New COVID-19 Booster and Flu Shot Available at Select Public ... - Mecklenburg County (.gov) - October 16th, 2023 [October 16th, 2023]
- Ban on COVID vaccine mandates by private businesses, including ... - The Texas Tribune - October 16th, 2023 [October 16th, 2023]
- What Are the Side Effects of the 2023 COVID Vaccine? Experts ... - Good Housekeeping - October 16th, 2023 [October 16th, 2023]
- Covid inquiry: Bereaved families relief as High Court dismisses Cabinet Office JR - openDemocracy - July 6th, 2023 [July 6th, 2023]
- UK health agency failed to account for 3.3bn of Covid inventory, say MPs - Financial Times - July 6th, 2023 [July 6th, 2023]
- COVID-19 Working Paper: Obesity Prevalence Among U.S. Adult ... - usda.gov - July 6th, 2023 [July 6th, 2023]
- California Changes Definition of COVID-19 Outbreak Easing the ... - Fisher Phillips - July 6th, 2023 [July 6th, 2023]
- New Study Shows Robust Pandemic Preparedness Strongly Linked ... - Nuclear Threat Initiative - July 6th, 2023 [July 6th, 2023]
- COVID-19 Infection Reduces the Risk of UTIs, Bacteremia, and ... - Contagionlive.com - July 6th, 2023 [July 6th, 2023]
- Europe Phases Out COVID-19 Flexible Regulations - Pharmaceutical Technology Magazine - July 6th, 2023 [July 6th, 2023]
- Travel Pains and COVID: How to Decide if You're Ready to Travel - CreakyJoints - July 6th, 2023 [July 6th, 2023]
- COVID Depression and Anxiety | Johns Hopkins Medicine - April 17th, 2023 [April 17th, 2023]
- Man declared dead due to Covid found 'shockingly' alive after 2 years in MP - Hindustan Times - April 17th, 2023 [April 17th, 2023]
- Senate votes to end Covid-19 emergency, 3 years after initial declaration - CNN - March 31st, 2023 [March 31st, 2023]
- DC COVID-19 centers closing Friday: Here's what you need to know - WJLA - March 31st, 2023 [March 31st, 2023]
- Can grade retention help with COVID-19 learning recovery in schools? - Brookings Institution - March 28th, 2023 [March 28th, 2023]
- On 3-year anniversary of COVID-19 in NC, Winston-Salem woman shares story of loss and healing after losing 2 loved ones - WXII12 Winston-Salem - March 4th, 2023 [March 4th, 2023]
- Oregon, Washington will lift mask requirements in health care settings on April 3 - KATU - March 4th, 2023 [March 4th, 2023]
- WHO says all theories for COVID origin 'remain on table' as lab leak theory gains traction - Sky News - March 4th, 2023 [March 4th, 2023]
- New COVID-19 omicron subvariant XBB.1.5 sweeping the nation, making up majority of cases - ABC Action News Tampa Bay - February 15th, 2023 [February 15th, 2023]
- Man gets 21 years in prison for stabbing wife in the Ozarks over COVID-19 stimulus check and their children - Law & Crime - February 15th, 2023 [February 15th, 2023]
- Healthline: Medical information and health advice you can trust. - January 2nd, 2023 [January 2nd, 2023]
- China can expect repeat Covid infections with new strains on the way: experts - South China Morning Post - January 2nd, 2023 [January 2nd, 2023]
- PCR tests for travellers reintroduced around the world as Covid-19 cases surge - The National - January 2nd, 2023 [January 2nd, 2023]
- Covid-19 surge after Covid-19 surge has made it impossible for US hospitals to plan for the future - Vox.com - January 2nd, 2023 [January 2nd, 2023]
- COVID-19 in China: Demand for a particular fruit rises as people seek natural remedies to fight the virus - WION - December 21st, 2022 [December 21st, 2022]